Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y

Editas Medicine (EDIT) incurred a loss of 75 cents per share in the third quarter of 2024, narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had reported a loss of 55 cents per share in the year-ago quarter.Collaboration and other research and development (R&D) revenues, which comprise the company’s top line, were $0.1 million in the reported quarter, down from$5.3 million reported in the year-ago quarter. The reported figure missed the Zacks Consensus Estimate of $7 million. Th ...